Last reviewed · How we verify
Injecting indocyanine green
At a glance
| Generic name | Injecting indocyanine green |
|---|---|
| Sponsor | LI XIN-XIANG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative (NA)
- Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer (NA)
- Using Indocyanine Green (ICG) to Outline Biliary Tree During Laparoscopic Cholecystectomy (PHASE4)
- Axillary Reverse Mapping in Breast Cancer (NA)
- Use of Indocyanine Green in Robotic Prostate Surgeries (PHASE4)
- Efficacy of Lymphovenous Bypass in the Treatment of Extremity Lymphedema
- Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG (NA)
- Carbon Nanoparticles vs Indocyanine Green (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Injecting indocyanine green CI brief — competitive landscape report
- Injecting indocyanine green updates RSS · CI watch RSS
- LI XIN-XIANG portfolio CI